Shenyang Xingqi Pharmaceutical Co.,Ltd.

300573

CNE100002DV1

SHENYANG XINGQI PHARMACEUTICAL CO., LTD. is a China-based company principally engaged in the research, development, manufacture and distribution of ophthalmic drugs. The Companyâs main products are ophthalmic prescription drugs, including corneal repairing drugs, anti-bacteria drugs, artificial tears, anti-inflammation drugs, anti-allergic drugs, as well as anti-hyperemia & fatigue relief drugs and others. The Company mainly distributes its products within domestic market.

Employees

1,995

Sector

Pharmaceuticals

Calendar

2024-10-23 - Q3 2024 Earnings Release (Projected)

More about the company

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

76.28

Average target price

Consensus

Profit revisions

Estimate revisions

Annual profits - Rate of surprise

Company calendar

End-of-day quote Shenzhen S.E. Other stock markets 2024-09-11			5-day change	1st Jan Change
76.28 ^CNY	-0.69%		-5.32%	-41.43%

08-29	Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Profit Distribution for First Half of 2024	CI
08-28	Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI

Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Profit Distribution for First Half of 2024	08-29	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	08-28	CI
Xingqi Pharmaceutical Gets Nod to Trial Eye Drops; Shares Up 4%	07-25	MT
Xingqi Pharmaceutical Gets Nod to Register Bromfenac Sodium Eye Drops; Shares Down 3%	07-24	MT
Space Peptides announced that it has received funding from Humanwell Healthcare Co.,Ltd., Shenyang Xingqi Pharmaceutical Co.,Ltd., Xiamen Furuier Pharmaceutical Co., Ltd., Purple Knight Capital and other investors	05-21	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Cash Dividend for 2023, Payable May 22, 2024	05-15	CI
Shenyang Xingqi Pharmaceutical's Q1 Profit Jumps 80%	04-26	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-25	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	04-18	CI
Xingqi Pharma Gets Nod to Market Atropine Sulfate Eye Drop; Shares Up 3%	03-13	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Approves Board Elections	01-08	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(SZSE:300573) added to Shenzhen Stock Exchange Component Index	12-12	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd.(SZSE:300573) added to Shenzhen Stock Exchange Component A Share Index	12-12	CI
Xingqi Pharmaceutical's Diquafosol Sodium Eye Drops Bags China's Centralized Drug Bid	11-08	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-23	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Announces Interim Dividend on A Shares for the Year 2023, Payable on 22 September 2023	23-09-18	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd Approves Cash Interim Profit Distribution Plan for 2023	23-09-14	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Proposes Interim Dividend for the First Half of 2023	23-08-29	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Xingqi Pharmaceutical Enrolls First Subject for Phase 4 Trial of Eye Drops	23-08-17	MT
Shenyang Xingqi Pharmaceutical Co.,Ltd Approves Cash Dividend for the Year 2022, Payable on 22 May 2023	23-05-12	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-26	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd Proposes Final Dividend for 2022	23-04-20	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-19	CI
Shenyang Xingqi Pharmaceutical Co.,Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022	22-10-26	CI

Shenyang Xingqi Pharmaceutical Co.,Ltd.

Equities